Literature DB >> 21430651

Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice.

Antonio Ortega-Alvaro1, Auxiliadora Aracil-Fernández, María S García-Gutiérrez, Francisco Navarrete, Jorge Manzanares.   

Abstract

The possible role of the CB(2) receptor (CB(2)r) in psychiatric disorders has been considered. Several animal models use knockout (KO) mice that display schizophrenia-like behaviors and this study evaluated the role of CB(2)r in the regulation of such behaviors. Mice lacking the CB(2)r (CB(2)KO) were challenged in open field, light-dark box, elevated plus-maze, tail suspension, step down inhibitory avoidance, and pre-pulse inhibition tests (PPI). Furthermore, the effects of treatment with cocaine and risperidone were evaluated using the OF and the PPI test. Gene expression of dopamine D(2) (D(2)r), adrenergic-α(2C) (α(2C)r), serotonergic 5-HT(2A) and 5-HT(2C) receptors (5-HT(2A)r and 5-HT(2C)r) were studied by RT-PCR in brain regions related to schizophrenia. Deletion of CB(2)r decreased motor activity in the OF test, but enhanced response to acute cocaine and produced mood-related alterations, PPI deficit, and cognitive impairment. Chronic treatment with risperidone tended to impair PPI in WT mice, whereas it 'normalized' the PPI deficit in CB(2)KO mice. CB(2)KO mice presented increased D(2)r and α(2C)r gene expressions in the prefrontal cortex (PFC) and locus coeruleus (LC), decreased 5-HT(2C)r gene expression in the dorsal raphe (DR), and 5-HT(2A)r gene expression in the PFC. Chronic risperidone treatment in WT mice left α(2C)r gene expression unchanged, decreased D(2)r gene expression (15 μg/kg), and decreased 5-HT(2C)r and 5-HT(2A)r in PFC and DR. In CB(2)KO, the gene expression of D(2)r in the PFC, of α(2C)r in the LC, and of 5-HT(2C)r and 5-HT(2A)r in PFC was reduced; 5-HT(2C)r and 5-HT(2A)r gene expressions in DR were increased after treatment with risperidone. These results suggest that deletion of CB(2)r has a relation with schizophrenia-like behaviors. Pharmacological manipulation of CB(2)r may merit further study as a potential therapeutic target for the treatment of schizophrenia-related disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21430651      PMCID: PMC3096817          DOI: 10.1038/npp.2011.34

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  98 in total

Review 1.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

2.  Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice.

Authors:  Hiroshi Nagai; Nobuaki Egashira; Kazunori Sano; Ayumi Ogata; Ai Mizuki; Kenichi Mishima; Katsunori Iwasaki; Yukihiro Shoyama; Ryoji Nishimura; Michihiro Fujiwara
Journal:  Pharmacol Biochem Behav       Date:  2006-07-03       Impact factor: 3.533

3.  Serotonin modulates fast-spiking interneuron and synchronous activity in the rat prefrontal cortex through 5-HT1A and 5-HT2A receptors.

Authors:  M Victoria Puig; Akiya Watakabe; Mika Ushimaru; Tetsuo Yamamori; Yasuo Kawaguchi
Journal:  J Neurosci       Date:  2010-02-10       Impact factor: 6.167

4.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

5.  Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia.

Authors:  T Karl; L Duffy; A Scimone; R P Harvey; P R Schofield
Journal:  Genes Brain Behav       Date:  2007-02-13       Impact factor: 3.449

6.  Short- and long-term memory are differentially regulated by monoaminergic systems in the rat brain.

Authors:  I Izquierdo; J H Medina; L A Izquierdo; D M Barros; M M de Souza; T Mello e Souza
Journal:  Neurobiol Learn Mem       Date:  1998-05       Impact factor: 2.877

Review 7.  Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications.

Authors:  Emmanuel S Onaivi
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

8.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

9.  Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain.

Authors:  Ildiko Racz; Xavier Nadal; Judith Alferink; Josep E Baños; Jennifer Rehnelt; Miquel Martín; Belén Pintado; Alfonso Gutierrez-Adan; Elena Sanguino; Jorge Manzanares; Andreas Zimmer; Rafael Maldonado
Journal:  J Neurosci       Date:  2008-11-12       Impact factor: 6.167

10.  Endocannabinoid signalling in the blood of patients with schizophrenia.

Authors:  Nicola De Marchi; Luciano De Petrocellis; Pierangelo Orlando; Fabiana Daniele; Filomena Fezza; Vincenzo Di Marzo
Journal:  Lipids Health Dis       Date:  2003-08-19       Impact factor: 3.876

View more
  67 in total

1.  Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice.

Authors:  Hai-Ying Zhang; Ming Gao; Qing-Rong Liu; Guo-Hua Bi; Xia Li; Hong-Ju Yang; Eliot L Gardner; Jie Wu; Zheng-Xiong Xi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

2.  Deletion of Type-2 Cannabinoid Receptor Induces Alzheimer's Disease-Like Tau Pathology and Memory Impairment Through AMPK/GSK3β Pathway.

Authors:  Lin Wang; Bing-Jin Liu; Yun Cao; Wei-Qi Xu; Dong-Sheng Sun; Meng-Zhu Li; Fang-Xiao Shi; Man Li; Qing Tian; Jian-Zhi Wang; Xin-Wen Zhou
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

3.  Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors.

Authors:  María S García-Gutiérrez; Borja García-Bueno; Silvia Zoppi; Juan C Leza; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

4.  Chronic activation of CB2 cannabinoid receptors in the hippocampus increases excitatory synaptic transmission.

Authors:  Jimok Kim; Yong Li
Journal:  J Physiol       Date:  2015-01-05       Impact factor: 5.182

5.  Identifying novel members of the Wntless interactome through genetic and candidate gene approaches.

Authors:  Jessica Petko; Trevor Tranchina; Goral Patel; Robert Levenson; Stephanie Justice-Bitner
Journal:  Brain Res Bull       Date:  2017-07-20       Impact factor: 4.077

6.  Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus.

Authors:  Y Li; J Kim
Journal:  Neuroscience       Date:  2015-10-26       Impact factor: 3.590

Review 7.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

8.  Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice.

Authors:  S Zoppi; J L Madrigal; J R Caso; M S García-Gutiérrez; J Manzanares; J C Leza; B García-Bueno
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

9.  Pharmacological effects of cannabinoids on the reference and working memory functions in mice.

Authors:  Avdesh Avdesh; Yikai Hoe; Ralph N Martins; Mathew T Martin-Iverson
Journal:  Psychopharmacology (Berl)       Date:  2012-08-19       Impact factor: 4.530

10.  Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling.

Authors:  Jade M Franklin; Gonzalo A Carrasco
Journal:  Synapse       Date:  2012-12-08       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.